TBPH Stock Summary and Trading Ideas (Theravance Biopharma - | NASDAQ:TBPH)

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Theravance Biopharma - trades on the NASDAQ stock market under the symbol TBPH.

As of April 17, 2026, TBPH stock price climbed to $17.23 with 385,774 million shares trading.

TBPH has a beta of 1.40, meaning it tends to be more sensitive to market movements. TBPH has a correlation of 0.13 to the broad based SPY ETF.

TBPH has a market cap of $887.22 million. This is considered a Small Cap stock.

Last quarter Theravance Biopharma - reported $46 million in Revenue and $1.15 earnings per share. This fell short of revenue expectation by $-8 million and exceeded earnings estimates by $.81.

In the last 3 years, TBPH traded as high as $21.03 and as low as $7.44.

The top ETF exchange traded funds that TBPH belongs to (by Net Assets): VTI, IWM, VXF, PBE, IBB.

TBPH has outperformed the market in the last year with a return of +100.5%, while the SPY ETF gained +36.5%. However, in the most recent history, TBPH shares have underperformed the stock market with its stock returning -13.9% in the last 3 month period and +7.6% for the last 2 week period, while SPY has returned +2.9% and +8.3%, respectively.

TBPH support price is $16.40 and resistance is $17.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TBPH shares will trade within this expected range on the day.